Literature DB >> 24743019

Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency.

Talal A Chatila1, Raif Geha1, Daifulah Al-Zahrani2, Ali Raddadi3, Michel Massaad1, Sevgi Keles1, Haifa H Jabara1.   

Abstract

The autosomal recessive form of the Hyper IgE syndrome (AR-HIES) with dedicator of cytokinesis 8 (DOCK8) deficiency is associated with difficult to treat persistent viral skin infections, including papilloma virus infection. Type I interferons play an important role in the defense against viruses. We examined the effect of therapy with IFN-α 2b in an 11-year old boy with DOCK8 deficiency due to a homozygous splice donor site mutation in DOCK8 intron 40. His unremitting warts showed dramatic response to IFN-α 2b therapy. Immunological studies revealed decreased circulating plasmacytoid dendritic cells (pDCs) and profound deficiency of IFN-α production by his peripheral blood mononuclear cells in response to treatment with CpG oligonucleotides. These findings indicate that underlying pDC deficiency and impaired IFN-α production may predispose to chronic viral infections in DOCK8 deficiency. IFN-α 2b therapy maybe useful in controlling recalcitrant viral infections in these patients.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  DOCK8 deficiency; Hyper -immunoglobulin E syndrome; Interferon–α 2b; Papilloma Virus; Warts

Mesh:

Substances:

Year:  2014        PMID: 24743019      PMCID: PMC4112510          DOI: 10.1016/j.clim.2014.04.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  15 in total

1.  Cutaneous manifestations of DOCK8 deficiency syndrome.

Authors:  Emily Y Chu; Alexandra F Freeman; Huie Jing; Edward W Cowen; Joie Davis; Helen C Su; Steven M Holland; Maria L Chanco Turner
Journal:  Arch Dermatol       Date:  2011-09-19

2.  DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses.

Authors:  Yosuke Harada; Yoshihiko Tanaka; Masao Terasawa; Markus Pieczyk; Katsuyoshi Habiro; Tomoya Katakai; Kyoko Hanawa-Suetsugu; Mutsuko Kukimoto-Niino; Tomoko Nishizaki; Mikako Shirouzu; Xuefeng Duan; Takehito Uruno; Akihiko Nishikimi; Fumiyuki Sanematsu; Shigeyuki Yokoyama; Jens V Stein; Tatsuo Kinashi; Yoshinori Fukui
Journal:  Blood       Date:  2012-03-28       Impact factor: 22.113

3.  Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells.

Authors:  Tomoki Ito; Holger Kanzler; Omar Duramad; Wei Cao; Yong-Jun Liu
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

4.  Differential requirement for DOCK2 in migration of plasmacytoid dendritic cells versus myeloid dendritic cells.

Authors:  Kazuhito Gotoh; Yoshihiko Tanaka; Akihiko Nishikimi; Ayumi Inayoshi; Munechika Enjoji; Ryoichi Takayanagi; Takehiko Sasazuki; Yoshinori Fukui
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

5.  Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.

Authors:  S A Gatz; U Benninghoff; C Schütz; A Schulz; M Hönig; U Pannicke; K-H Holzmann; K Schwarz; W Friedrich
Journal:  Bone Marrow Transplant       Date:  2010-07-12       Impact factor: 5.483

Review 6.  Plasmacytoid dendritic cells: recent progress and open questions.

Authors:  Boris Reizis; Anna Bunin; Hiyaa S Ghosh; Kanako L Lewis; Vanja Sisirak
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

7.  Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome.

Authors:  Karin R Engelhardt; Sean McGhee; Sabine Winkler; Atfa Sassi; Cristina Woellner; Gabriela Lopez-Herrera; Andrew Chen; Hong Sook Kim; Maria Garcia Lloret; Ilka Schulze; Stephan Ehl; Jens Thiel; Dietmar Pfeifer; Hendrik Veelken; Tim Niehues; Kathrin Siepermann; Sebastian Weinspach; Ismail Reisli; Sevgi Keles; Ferah Genel; Necil Kutukculer; Necil Kutuculer; Yildiz Camcioğlu; Ayper Somer; Elif Karakoc-Aydiner; Isil Barlan; Andrew Gennery; Ayse Metin; Aydan Degerliyurt; Maria C Pietrogrande; Mehdi Yeganeh; Zeina Baz; Salem Al-Tamemi; Christoph Klein; Jennifer M Puck; Steven M Holland; Edward R B McCabe; Bodo Grimbacher; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

8.  Combined immunodeficiency associated with DOCK8 mutations.

Authors:  Qian Zhang; Jeremiah C Davis; Ian T Lamborn; Alexandra F Freeman; Huie Jing; Amanda J Favreau; Helen F Matthews; Joie Davis; Maria L Turner; Gulbu Uzel; Steven M Holland; Helen C Su
Journal:  N Engl J Med       Date:  2009-09-23       Impact factor: 91.245

9.  Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.

Authors:  Kazuhito Gotoh; Yoshihiko Tanaka; Akihiko Nishikimi; Risa Nakamura; Hisakata Yamada; Naoyoshi Maeda; Takahiro Ishikawa; Katsuaki Hoshino; Takehito Uruno; Qinhong Cao; Sadayuki Higashi; Yasushi Kawaguchi; Munechika Enjoji; Ryoichi Takayanagi; Tsuneyasu Kaisho; Yasunobu Yoshikai; Yoshinori Fukui
Journal:  J Exp Med       Date:  2010-03-15       Impact factor: 14.307

10.  DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice.

Authors:  Katrina L Randall; Stephanie S-Y Chan; Cindy S Ma; Ivan Fung; Yan Mei; Mehmet Yabas; Andy Tan; Peter D Arkwright; Wafaa Al Suwairi; Saul Oswaldo Lugo Reyes; Marco A Yamazaki-Nakashimada; Maria de la Luz Garcia-Cruz; Joanne M Smart; Capucine Picard; Satoshi Okada; Emmanuelle Jouanguy; Jean-Laurent Casanova; Teresa Lambe; Richard J Cornall; Sarah Russell; Jane Oliaro; Stuart G Tangye; Edward M Bertram; Christopher C Goodnow
Journal:  J Exp Med       Date:  2011-10-17       Impact factor: 14.307

View more
  13 in total

1.  Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes TH17 cell differentiation.

Authors:  Sevgi Keles; Louis Marie Charbonnier; Venkataraman Kabaleeswaran; Ismail Reisli; Ferah Genel; Nesrin Gulez; Waleed Al-Herz; Narayanaswamy Ramesh; Antonio Perez-Atayde; Neslihan E Karaca; Necil Kutukculer; Hao Wu; Raif S Geha; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2016-05-24       Impact factor: 10.793

Review 2.  Insights into immunity from clinical and basic science studies of DOCK8 immunodeficiency syndrome.

Authors:  Helen C Su; Huie Jing; Pam Angelus; Alexandra F Freeman
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

Review 3.  DOCK8 deficiency: Insights into pathophysiology, clinical features and management.

Authors:  Catherine M Biggs; Sevgi Keles; Talal A Chatila
Journal:  Clin Immunol       Date:  2017-06-15       Impact factor: 3.969

4.  DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients.

Authors:  Susanne E Aydin; Sara Sebnem Kilic; Caner Aytekin; Ashish Kumar; Oscar Porras; Leena Kainulainen; Larysa Kostyuchenko; Ferah Genel; Necil Kütükcüler; Neslihan Karaca; Luis Gonzalez-Granado; Jordan Abbott; Daifulah Al-Zahrani; Nima Rezaei; Zeina Baz; Jens Thiel; Stephan Ehl; László Marodi; Jordan S Orange; Julie Sawalle-Belohradsky; Sevgi Keles; Steven M Holland; Özden Sanal; Deniz C Ayvaz; Ilhan Tezcan; Hamoud Al-Mousa; Zobaida Alsum; Abbas Hawwari; Ayse Metin; Susanne Matthes-Martin; Manfred Hönig; Ansgar Schulz; Capucine Picard; Vincent Barlogis; Andrew Gennery; Marianne Ifversen; Joris van Montfrans; Taco Kuijpers; Robbert Bredius; Gregor Dückers; Waleed Al-Herz; Sung-Yun Pai; Raif Geha; Gundula Notheis; Carl-Philipp Schwarze; Betül Tavil; Fatih Azik; Kirsten Bienemann; Bodo Grimbacher; Valerie Heinz; H Bobby Gaspar; Roland Aydin; Beate Hagl; Benjamin Gathmann; Bernd H Belohradsky; Hans D Ochs; Talal Chatila; Ellen D Renner; Helen Su; Alexandra F Freeman; Karin Engelhardt; Michael H Albert
Journal:  J Clin Immunol       Date:  2015-01-28       Impact factor: 8.317

Review 5.  Current Status of Dedicator of Cytokinesis-Associated Immunodeficiency: DOCK8 and DOCK2.

Authors:  Dimana Dimitrova; Alexandra F Freeman
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

Review 6.  Primary immunodeficiency update: Part I. Syndromes associated with eczematous dermatitis.

Authors:  Dominique C Pichard; Alexandra F Freeman; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2015-09       Impact factor: 11.527

Review 7.  Recent Advances in DOCK8 Immunodeficiency Syndrome.

Authors:  Qian Zhang; Huie Jing; Helen C Su
Journal:  J Clin Immunol       Date:  2016-05-20       Impact factor: 8.317

Review 8.  Hyper-IgE Syndromes and the Lung.

Authors:  Alexandra F Freeman; Kenneth N Olivier
Journal:  Clin Chest Med       Date:  2016-06-10       Impact factor: 2.878

9.  Delayed control of herpes simplex virus infection and impaired CD4(+) T-cell migration to the skin in mouse models of DOCK8 deficiency.

Authors:  Inge E A Flesch; Katrina L Randall; Natasha A Hollett; Hsei Di Law; Lisa A Miosge; Yovina Sontani; Christopher C Goodnow; David C Tscharke
Journal:  Immunol Cell Biol       Date:  2015-03-17       Impact factor: 5.126

10.  Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene.

Authors:  Karin E Lundin; Abdulrahman Hamasy; Paul Hoff Backe; Lotte N Moens; Elin Falk-Sörqvist; Katja B Elgstøen; Lars Mørkrid; Magnar Bjørås; Carl Granert; Anna-Carin Norlin; Mats Nilsson; Birger Christensson; Stephan Stenmark; C I Edvard Smith
Journal:  Clin Immunol       Date:  2015-10-19       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.